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diameter (MLD) pra-PTCA (p = 0.02) and MLD post-CS (p = 0.03) were
related to restenosis. Multivariate analysis (logistic regression) identified the
presenee of diabatee (odds ratio [OR]: 3.5, Cl 95%: 1.4-6.1), number of
stenta par Ieaion (OR 3.1, Cl 95%: 1.2-7.4) and MLD post-CS (OR 0.3, Cl
95%: 0.1+.6) as independent pradietors of R.
Thus: 1) Despite the baseline unfavorable characteristicsof this sample,
a low rate of clinical and angiographic Rafter CS was observed; 2) MLD after
CS, number of stenta per lesion and diabetes were identified as independent
pradietots of restenoais.
1973-681 QuanttitiveAngiographic Pmditiorsof
Reetenoeie efter the Lees Shortening Wellstent
Impientetion
Y.Ozaki, A.G. Violaris, M. Nobuyoshi, H. Yokoi, T. Kobayashi, P.Serruys.
Thoraxcentac Erasmus Uni~, Rotterdam, NL, Dept. of Cardiology Kokuni
Memorial Hospital, Kitakyuayu, Japan, Aichi Medicel lhi~, Nagoya, Japan
The maehanism of stent restenosla still remains unknown. To identify the
arsgiographic predictors of stent restenosis, we performed a retrospective
analysis in 72 patients with the Wallstent implantation and complete set of
quantitative angiographic analysis (pre and post procedure and 6 month
follow-up [fup]). Twenty-one patients (29%) had restenosis (250% diameter
stenosis at fup). Minimal Iuminal diameter (MLD), lesion length and reference
vessel size were measured by QCA system (CAAS 11).Proximal reference
veeael diameter (pmx RD) and distal reference vessel diameter (distal RD)
ware mmpared with Wallstent diameter used (VW diam).
Non-reetenosis Restenosis D-vslus
(51 Patients) (21 patients)
LesionLenoth(mm) 28.8 + 12.1 35.4+ 11.0 <0.05
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Lesion length, MLD post, distal vessel size and the degree of the over-
sizing of Wallstent (compared to distal vessei size) significantly related to
greater Iuminal lose at fup. Diffuse iong iesion in the small distai vessel
may predispose to subsequent restenoais. Operatore should avoid exces-
sive oversizing in the selection of Wallstent and stenting in small distal vessel
to lessen the risk of late restenosis.
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Angioplasty in Intrastent Reatenoaia
F. Schiele, N. Meneveau, A. Vuillemenot, S. Gupta, D.D. Zhang,
J.-P. Baaaand. H6pital Universitaire Saintdacques, 25000 Besan~on,
France
Optimal treatment of restenosis occurring after coronary stenting, is not yet
clear even if balloon angioplaety (PTCA) has been demonstrated safe and
efficient. The mechanism of balloon angioplasty in intrastent restenosis was
studied with Quantitative Coronary Angiography (QCA) and Intra Coronaw
Ultra Sound (ICUS) in20 Pte.All Ptsweredilatad with a noncompliant balloon
inflated at high pressure (=-15atm), QCA and ICUS data were available for
ail Pta at stent implantation (basal), before and after repeat (PTCA). Minimal
Lumen Diameter (MLD) was assessed with QCA, and vessel size (EEM),
etent cross sectional area, Lumen area and the neo intimal tissue area (Stent
area -Lumen area) with ICUS.
Bessl Before RePTCA RePTCA
MLD (mm) 2.4+ 0,5 0.7* 0.6 1.9 * 0,7
EEM (mn#) 12.9 &2.6 15.0 * 3.7 15.9+ 3,6
Stsnt ares (mrr#) 7.1 + 1.6 7.9+2.0 6.5+ 1.5
Lumenarea (mr#) 7.1 + 1.6 3.2 & 1.1 5.6+ 1.0
Nan inttieeue (mn#) 3.9* 1.5 3.09 + 1.6
Stent area increased after rePTCA, but most of the naointimal tissue
remained within the stent thus explaining that despite 8tent overexpansion,
MLD and Lumen area were lower after RePTCA than at initial stent implan-
tation (respectively, 2.4 A 0.5 vs 1.9 + 0.7 mm, p c 0.05 and 7.1 + 1.6 vs
5.6 + 1.0 mt#, p < 0.01).
We conclude that the mechanism of balloon angioplasly in intrastent
restenoeis is mainiy overexpansion of the stent, most of the naointimal tissue
remaining within the stent.
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1974-83/ Addition ofaPlateletG@oprotelnlM llaMibitor
to Heparin + Aepirin Decreaaee Ex-Vivo Thrombua
Formation After Percutaneous Coronary
Intervention
G.Dangas, J.J, Badimon, J.A. Ambrose, B.S. Coller, J.T. Fallen,
A.M. Cohen, P.Meraj, R. Hayes, S.K. Sharma, J.D. Marmur. The
cardiovascular hEfitU@, Mount Sinai Medical Cente~ Naw york,A/y USA
Although c7E3 Fab, a Gp llb/llla inhibitor, decreases complications after
PTCA, its effect on thrombus formation in these patients is unknown. To
quantify the antithrombotic effects of standard dose c7E3 Fab, we studied 19
patients (60 + 2 yrs, 75% men) undergoing coronary intewention using an
ex-vivo perfusion chamber. Through a venous eannula, blcmdwaspumped
directly from the patient and circulated, under eontroilsxl rhsologic renditions
of high shear rate simulating mild arterial stenosis (1690 a-l), through a
chamber containing a standard thrombogenic substrate (injured porcine aor-
tic media). Perfusion runs were performed on heparin + aspirin prior to the
procedure in ali patients and then repeated 2 hours after the proesdure on
aspirin + heparin alone (Group 1; n = 10) or on aspirin + heparin + c7E3 Fab
(Group 2; n = 9). To quantify thrombus, chamber specimens were stainad
with trichrome and for fibrinogen and platelet ‘factor 4. The cross-saetionai
area of the thrombus (TA; &m2) was measured on 9 sections par chamber
run with computerized planimetry. TA for each condition as mean + SE:
Group1 Group2 P
TA preprocedure 12526 + 1506 16575 + 1566 NS
TA postprocedure 13953 + 1510 S603 + 930 0.04
p (withingroup) NS <0.001
There was no difference between groups in baseline Hot, platelet oount,
preprocsdure PTT,and periprocedure ACT (291 +23 s).
Conclusion: The addition of c7E3 Fab to heparin + aspirin significantly
decreases the propensity to form thrombus on an injured arterial aurface,
providing an insight into the mechanism by which c7E3 Fab reduces pari-
procedurai complications.
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llb/llla Receptor Blockade During Coronary
Intervention in the EPILOG Trial
A.M. Lincoff, D.B. Mark, R.M. Calilf, J.E. Tcheng, S.G. Ellis,
L. Davidson-Ray, K.M. Andere~, G.L. Stoner, E.J. Topol. C/eve/and C/in/c
Foundation, Cleveland, OH, USA
In the 2099 pt EPIC trial, use of abciximab (c7E3 Fab, RaoPro) during
coronary intervention decreased baseline hospitalization cost aasoeiatad
with ischemic complications, but savings were offset by costs of increased
bleeding complications. The subsequent EPILOG trial demonstrated in 2792
pts that hemorrhagic risk associated with abciximab therapy ean be nearly
eliminated by reduction of heparin dosing, Using the Economic Model and
cost data derived from the EPIC trial, in-hospital costs of treatment with
abciximab in the EPILOG trial were estimated.
EPIC (observed$) EPILOG (estimated $)
Plscebo Abciximab Placebo Abciximab
IschemicEvents 15.4% 12.9”/. 13,9”/0 8.0%
Uraent CABG 3.64A 2.4% 1.7% 0.4%
M~or Bleed 3.3”A 10.6% 1.1% 1.10%
BaselineCoet $13,4S4 $13,577 $12,767
AbciximabCost
$12,260
$1407 $1407
in-HospCost $13,43; $14,9S4 $12,76; $13,ss7
in-Hosp Difference $1550 $660
F/U Difference ($1270) savings pending
TotalCost perpt $260 pending
in-hospital costs of abciximabtherapy are approximately halved by control
of bleeding risk. Thus, with the heparin regimen from EPILOG, initial data
suggest that abeiximab may incur sufficient cost savings over6 months to pay
for itself. Complete prospectively-collected in-hospital and 6-month madieel
cost data from EPILOG will be presentad.
